Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics symbols : Ruby save search
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
Published: 2024-02-06 (Crawled : 12:00) - globenewswire.com
TCRX 1 d | $6.9 2.22% 2.17% 250K
|
Professional, Scientific, and T...
|
| O: 1.08%
H: 7.31%
C: 5.53%
ALRN | $5.01 17.88% 15.17% 1.8M
|
Health Technology
|
| O: -0.3%
H: 2.58%
C: -7.08%
therapeutics
COUR Pharmaceuticals Appoints Dannielle Appelhans as Chief Operating Officer
Published: 2023-07-19 (Crawled : 13:20) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.04%
H: 0.8%
C: 0.48%
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 7.98%
H: 0.0%
C: 0.0%
GBIO | $2.775 -6.88% -7.39% 200K
|
Health Technology
|
| O: -0.19%
H: 9.21%
C: -1.73%
pharmaceuticals
Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel
Published: 2023-02-28 (Crawled : 14:00) - globenewswire.com
AKYA | $3.855 -1.41% -1.43% 260K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.27%
C: -5.41%
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.23%
H: 14.07%
C: 10.95%
PRGS S | $50.18 -0.81% -0.82% 540K
|
Technology Services
|
| O: -0.61%
H: 0.8%
C: 0.44%
Cellarity Announces Close of $121 Million Series C Financing
Published: 2022-10-04 (Crawled : 12:00) - biospace.com/
OMGA | $2.42 -5.28% -5.58% 360K
|
|
| O: 0.0%
H: 9.59%
C: 6.97%
SANA | $7.74 -6.3% -6.72% 1.9M
|
|
| O: 3.0%
H: 4.68%
C: 4.36%
MCRB | $0.589 -6.11% -6.5% 3.8M
|
Health Technology
|
| O: 2.1%
H: 2.85%
C: 2.69%
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.82%
H: 7.34%
C: 6.96%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 2.22%
H: 2.22%
C: 1.62%
FHTX | $5.58 -3.46% -3.58% 130K
|
Health Technology
|
| O: 3.15%
H: 7.96%
C: 3.06%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 0.95%
H: 7.55%
C: 6.6%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: 2.26%
H: 2.33%
C: 1.48%
Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
Published: 2022-09-19 (Crawled : 14:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 3.28%
H: 0.0%
C: -6.78%
conference therapeutics
Rubius Therapeutics to Provide Strategic Update
Published: 2022-09-12 (Crawled : 21:00) - globenewswire.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -20.56%
H: 14.12%
C: 9.06%
therapeutics update
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior
Published: 2022-08-17 (Crawled : 13:20) - biospace.com/
OMGA | $2.42 -5.28% -5.58% 360K
|
|
| O: -3.81%
H: 6.17%
C: 0.44%
SANA | $7.74 -6.3% -6.72% 1.9M
|
|
| O: -1.77%
H: 2.83%
C: -2.57%
MCRB | $0.589 -6.11% -6.5% 3.8M
|
Health Technology
|
| O: -1.79%
H: 2.55%
C: -1.09%
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.53%
H: 3.24%
C: -4.97%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -1.74%
H: 1.56%
C: -4.27%
FHTX | $5.58 -3.46% -3.58% 130K
|
Health Technology
|
| O: -0.86%
H: 3.89%
C: 1.79%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -1.52%
H: 4.61%
C: 0.0%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: -0.99%
H: 1.2%
C: -1.9%
computational
Senda Biosciences Announces Close of $123 Million Series C Financing
Published: 2022-08-16 (Crawled : 12:00) - biospace.com/
OMGA | $2.42 -5.28% -5.58% 360K
|
|
| O: -2.4%
H: 3.28%
C: -3.28%
SANA | $7.74 -6.3% -6.72% 1.9M
|
|
| O: -0.12%
H: 0.47%
C: -6.05%
MCRB | $0.589 -6.11% -6.5% 3.8M
|
Health Technology
|
| O: -1.58%
H: 0.89%
C: -0.18%
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -0.19%
H: 1.89%
C: -2.77%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.44%
H: 2.35%
C: -4.57%
FHTX | $5.58 -3.46% -3.58% 130K
|
Health Technology
|
| O: -2.86%
H: 4.55%
C: 0.37%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: -5.04%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: -0.35%
H: 0.08%
C: -3.34%
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
Published: 2022-07-26 (Crawled : 17:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.0%
H: 1.71%
C: -4.11%
therapeutics results
HotSpot Therapeutics Appoints Jose Carmona to Board of Directors
Published: 2022-07-19 (Crawled : 12:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 3.55%
H: 0.0%
C: -0.01%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 4.22%
H: 0.26%
C: -0.22%
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 2.44%
H: 0.55%
C: -3.57%
therapeutics
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
Published: 2022-07-14 (Crawled : 15:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 3.13%
H: 1.28%
C: -1.6%
therapeutics
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
Published: 2022-06-22 (Crawled : 14:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -11.73%
H: 21.91%
C: 14.92%
preclinical immunology meeting program therapeutics diabetes pre-clinical
Induction of Antigen-Specific Immune Tolerance in Type 1 Diabetes by Antigen-Expressing Red Cell Therapeutics
Published: 2022-06-22 (Crawled : 12:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -11.73%
H: 21.91%
C: 14.92%
therapeutics diabetes
Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer
Published: 2022-06-02 (Crawled : 12:00) - biospace.com/
OMGA | $2.42 -5.28% -5.58% 360K
|
|
| O: -14.29%
H: 18.41%
C: 9.95%
SANA | $7.74 -6.3% -6.72% 1.9M
|
|
| O: -6.1%
H: 9.2%
C: 8.6%
MCRB | $0.589 -6.11% -6.5% 3.8M
|
Health Technology
|
| O: -2.98%
H: 5.18%
C: 3.24%
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -12.16%
H: 2.29%
C: -5.11%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -3.65%
H: 1.64%
C: -0.01%
FHTX | $5.58 -3.46% -3.58% 130K
|
Health Technology
|
| O: -3.44%
H: 4.99%
C: -2.54%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 13.76%
H: 8.47%
C: 7.66%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: -3.1%
H: 2.86%
C: 2.15%
therapeutics
A Phase 1/2 Study of RTX-224, an Engineered Red Blood Cell Expressing 4-1BB Ligand and Membrane-Bound IL-12, for the Treatment of Patients with Select Advanced Solid Tumors
Published: 2022-05-26 (Crawled : 21:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 1.89%
H: 10.19%
C: 10.19%
rtx-224 treatment blood phase 1
Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors
Published: 2022-05-24 (Crawled : 18:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.99%
H: 1.96%
C: 1.96%
therapeutics
Cellarity Appoints Dr. Sandra Horning to Board of Directors
Published: 2022-05-09 (Crawled : 13:00) - biospace.com/
OMGA | $2.42 -5.28% -5.58% 360K
|
|
| O: 11.29%
H: 1.97%
C: -25.63%
SANA | $7.74 -6.3% -6.72% 1.9M
|
|
| O: -11.66%
H: 1.75%
C: -9.06%
SGTX | $22.47 -2.56% 0.0% 0
|
Health Technology
|
| O: -0.27%
H: 2.59%
C: -5.55%
MCRB | $0.589 -6.11% -6.5% 3.8M
|
Health Technology
|
| O: -10.96%
H: 0.0%
C: 0.0%
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 2.17%
H: 2.84%
C: -5.67%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -5.14%
H: 6.67%
C: 2.27%
FHTX | $5.58 -3.46% -3.58% 130K
|
Health Technology
|
| O: -2.69%
H: 0.61%
C: -5.9%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -1.21%
H: 2.04%
C: -7.35%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: -4.06%
H: 4.81%
C: 0.62%
CDAK | $0.057 -55.99% -131.25% 0
|
Health Technology
|
| O: -4.51%
H: 0.0%
C: -11.89%
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: -1.66%
H: 2.81%
C: -2.25%
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
Published: 2022-04-26 (Crawled : 14:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -3.74%
H: 6.0%
C: -2.78%
therapeutics results
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform
Published: 2022-04-19 (Crawled : 14:00) - biospace.com/
OMGA | $2.42 -5.28% -5.58% 360K
|
|
| O: -0.56%
H: 4.31%
C: -4.13%
SANA | $7.74 -6.3% -6.72% 1.9M
|
|
| O: -0.13%
H: 2.81%
C: 0.67%
SGTX | $22.47 -2.56% 0.0% 0
|
Health Technology
|
| O: 3.05%
H: 2.22%
C: -1.48%
MCRB | $0.589 -6.11% -6.5% 3.8M
|
Health Technology
|
| O: 0.89%
H: 3.51%
C: 1.93%
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.58%
H: 1.74%
C: -6.98%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -8.13%
H: 1.25%
C: 0.63%
FHTX | $5.58 -3.46% -3.58% 130K
|
Health Technology
|
| O: 0.38%
H: 2.4%
C: 0.3%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 0.43%
H: 1.3%
C: -0.43%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: 1.12%
H: 1.72%
C: -1.87%
CDAK | $0.057 -55.99% -131.25% 0
|
Health Technology
|
| O: 0.0%
H: 3.63%
C: -1.04%
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: 0.0%
H: 3.11%
C: 1.55%
therapeutics platform
Phase 1 Trial of RTX-240, Allogeneic Red Blood Cells Engineered to Express 4-1BBL and Trans-Presented IL-15, in Patients with Advanced Solid Tumors
Published: 2022-04-08 (Crawled : 17:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 1.19%
H: 2.28%
C: -46.21%
rtx-240 blood trial phase 1
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.